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Previewsand receptor downregulation (Spangler
et al., 2010). Antibody combinations are
now being tested in HER2-positive breast
cancer (http://www.clinicaltrials.gov).
Overall, the findings reported by Tvoro-
gov and colleagues define a novel class of
anti-VEGFR-3 antibody that blocks ho-
modimerization and heterodimerization
of receptors and complements the ac-
tivity of antibodies that block ligand-
binding. This work provides mechanistic
insights into receptor dimerization and
the promise of using inhibitors of dimer-
ization as a biologically meaningful ap-
proach for suppressing angiogenesis
and lymphangiogenesis and potentially
tumor growth and dissemination. Be-
cause VEGFR-3 is one of the most highly
upregulated therapeutic targets in endo-
thelial cells of tumor vessels, the receptor
could also serve as a target for antibodies
coupled to therapeutic cargo such as
radioisotopes, liposomes, or nanopar-
ticles loaded with cytotoxic therapeutics,
or even T cells.This novel class of inhibitors has the
potential of outperforming conventional
competitive inhibitors of angiogenesis
because of the insensitivity to ligand
concentration and the ability to inhibit
heterodimerization and influence multiple
downstream signaling pathways. The use
of an antidimerization antibody in combi-
nation with an antiligand binding antibody
could translate into clinical benefit from
more potent antiangiogenic and antilym-
phangiogenic activities. Further validation
of the efficacy of antibody combinations
in preclinical models could pave the way
for inhibitors that block tumor angiogen-
esis and lymph node metastasis in cancer
patients.
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In this issue of Cancer Cell, Anido et al. demonstrate that Id1 is the likely arbiter of divergent transforming
growth factor-b (TGF-b) signaling in glioma-initiating cells (GICs) from different tumors. These findings
hold both the promise and potential peril of therapeutic targeting of the TGF-b pathway.Human glioblastoma derived GICs have
stem cell properties of self-renewal and
differentiation with genotypes and pheno-
types similar to their parental tumors and
substantially different from conventional
glioma cell lines (Lee et al., 2006). In addi-
tion, there is evidence suggesting that
GICs can promote tumor angiogenesis
and mediate radiotherapy resistance
(Bao et al., 2006). With the increasing evi-
dence that GICs are the stem cell sub-
component of malignant gliomas, there
are reasons to believe that targeting
GICs hold great therapeutic potential.Terminal differentiation is a powerful
tumor suppressor mechanism, and thus
there is keen interest in finding ways to
activate cancer stem cell differentiation
programs for therapeutic purposes.
As the founding member of a group of
more than 40 secreted factor family
members, TGF-b plays an intricate role
in the regulation of almost all cell types
in the body, with an emphasis on control-
ling homeostasis and developmental
processes including stem cell differentia-
tion. The effects of TGF-b signaling
are mediated through transmembraneserine-threonine type I (TbRI) and type II
(TbRII) receptors that phosphorylate
Smad proteins, which then forward
signals from the TGF-b receptors to the
nucleus where they regulate transcription.
The role of TGFb in cancer stem cell differ-
entiation is of significant interest given its
overexpression in a number of tumors
including lung, colon, and gastric carci-
noma as well as in high-grade gliomas.
TGF-b had been previously shown to
increase the self-renewal and oncogenic
potential of GICs, although the mecha-
nism was not known (Penuelas et al.,ecember 14, 2010 ª2010 Elsevier Inc. 543
Figure 1. The Cellular Response to TGF-b Activity Depends, in Part, on Id1 Activation or Repression
(A) TGF-b binding to type I (TbRI) and type II (TbRII) receptors leads to Smad activation and Smad binding to TGF-b-responsive elements located at the Id1
promoter. The resulting cellular response (e.g., self-renewal, differentiation) is cell context dependent.
(B) In epithelial cells, the availability of the TNF-a associated transcriptional co-repressor, ATF3, in conjunction with the Smad complex results in transcription
repression of Id1.
(C) In many, but not all, glioma initiating cells (GICs), ATF3 is not produced, leading to Smad-mediated Id1 transcriptional activation.
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Previews2009). An important clue as to how this
might occur came with the demonstration
that TGF-b could induce the transcription
factor, inhibitor of DNA binding 1 (Id1), in
tumor cells (Padua et al., 2008).
The family of Id proteins is highly
expressed in embryonic tissue and in the
stem/progenitor cell compartment of
some adult tissues. Id proteins have a
primary role in antagonizing cellular differ-
entiation through the dominant negative
inhibition of DNA-binding helix-loop-helix
transcription factors. It was recently
shown that Id1 expression was necessary
for the self-renewal capacity of adult
neural stem cells (Nam and Benezra,
2009). Along with their role in normal
development, Ids are overexpressed in
several different tumor types, and recently
Id1 and Id3 expression was shown to be
necessary for tumor initiation and metas-
tasis in triple-negative human breast
cancer (Gupta et al., 2007). Anido and544 Cancer Cell 18, December 14, 2010 ª20colleagues now build on these findings
by showing that TGF-b can induce
expression of Id1 and Id3 in GICs
in vitro. By contrast, blockade of TGF-b
downstream signaling by a specific TbRI
inhibitor significantly inhibited Id1 expres-
sion, resulting in decreased GIC neuro-
sphere proliferation in vitro and tumorige-
nicity in vivo (Anido et al., 2010).
A paracrine/autocrine mechanism of
glioma TGF-b overexpression leading to
Id1/3 induction with subsequent GIC
proliferation would seem straightforward
and conducive to therapeutic interven-
tions aimed at inhibiting TGF-b signaling.
This, however, is undermined by the
complexity of TGF-b signaling. Although
TGFb has long been implicated as a pro-
oncogenic factor in a number of cancers,
it has also been shown to have tumor
suppressor affects through regulation of
cell proliferation, differentiation, survival,
and its effects on the tumor microenviron-10 Elsevier Inc.ment. It should, therefore, not be sur-
prising that TGF-b can not only induce
Id1 expression but can also repress its
expression depending on the cellular con-
text. Thus, TGF-b can induce Id1 expres-
sion in both GICs and in breast cancer
cells while repressing its expression in
normal epithelia and endothelial cells
(Massague, 2008; Anido et al., 2010). As
a master regulator of cellular transcrip-
tional networks, these observations sug-
gest that Id1/3 may mediate a number of
the pleotropic effects of TGF-b signaling
on cellular biology.
Anido et al. provide a piece to the
puzzle of how TGFb signaling can cause
such divergent effects on Id1 expression
by showing that both transcriptional
induction and repression is mediated
through the same TGF-b responsive
element in the Id1 upstream promoter. In
epithelial cells, however, TGF-b signaling
occurs in the setting of TNF-a activation
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Previewsleading to the induction of the transcrip-
tional repressor, ATF3, which binds to
TGF-b-activated Smad proteins forming
a repressor complex that then binds to
the TGF-b binding element in the Id1
promoter (Kang et al., 2003). Anido et al.
show, however, that ATF3 is not ex-
pressed in GICs so TGF-b-mediated
activated Smads bind to the consensus
element in the Id1 promoter without the
ATF3 repressor protein, thus mediating
transcriptional activation rather than
repression (Figure 1). This suggests that
the repression of Id1, and the subsequent
cellular response initiated by TGF-b sig-
naling, depends upon TNFa pathway
activation in GICs.
The complexity of the TGF-b signaling
pathway and its dependence on cellular
context gives one pause before con-
cluding that TGF-b inhibition will be a
promising therapeutic strategy for all
gliomas. In fact, Anido and coworkers
reported that one of their patient-derived
GIC lines responded to TGF-b inhibition
with induction, rather than repression, of
Id1. TGF-b inhibition could, therefore,
have a pro-proliferative, pro-oncogenic
affect on gliomas with inducible Id1
biology. Thus, in theory, one would opti-
mally like to screen GICs from each
patient’s tumor in order to select for
patients likely to benefit from therapeutic
inhibition of TGF-b signaling. This is
impractical, however, given the time,
expense, required expertise, and ineffi-
ciency of deriving such cells from patients
in real time. Thus, amore thoroughmolec-
ular understanding of TGF-b signaling in
GICs with divergent responses to TGF-b
is necessary. For example it would be
interesting to determine whether there
were defects in TbRI, TbRII, or down-
stream components in the TGF-b sig-
naling pathway that, like ATF3, affect Id1
induction or repression with subsequentaffects on GIC tumorigenicity. Addition-
ally, studies evaluating the posttransla-
tional modification of TGF-b pathway
components, such as the ubiquination
of Smads, will probably be informative
(Dupont et al., 2009).
Through such mechanistic studies of
GIC lines with divergent responses to
TGF-b inhibition, we will hopefully identify
clinically useful biomarkers that will be
predictive of tumor sensitivity to thera-
peutic TGF-b inhibition. Unfortunately, the
complexity of translating such studies to
the clinic does not end there for it is known
that TGF-b has significant effects on the
host immune systemandon the tumormir-
coenvironment. Thus, even if biomarkers
predictiveofGICsensitivity toTGF-b inhibi-
tion in vitro canbe identified, systemic inhi-
bition of the TGF-b signaling pathway will
have unknown and likely heterogeneous
effects on different patients that will un-
doubtedly impact on the clinical efficacy
of this therapeutic strategy.
The attraction of targeting tumor stem
cell and developmental pathways is
tempting and there are growing preclinical
data, such as those by Anido et al., to
suggest the potential benefits of doing
so. The enthusiasm for such a strategy,
however, must be tempered by the
appreciation of the complexity and
cellular context-dependent nature of
these gene regulatory networks that are
susceptible to both cell intrinsic and cell
extrinsic (environmental) perturbations.
The complexity of these stem cell
networks is further confounded by affects
from the diversity of genomic and epi-
genomic aberrations found within the
landscape of the cancer genome. This
diversity will undoubtedly contribute to
divergent responses to therapeutic inter-
ventions aimed at targets within these
networks. Nevertheless, with our increas-
ing ability to interrogate individual tumorCancer Cell 18, Dgenomes at the sequence, expression
and epigenomic level, combined with
improved model systems, the under-
standing of the structure and function of
these stem cell and developmental net-
works now seems to be within reach.
Studies such as the one presented here
by Anido et al. will help to elucidate vital
nodes within these cancer-dependent
developmental networks and hopefully
help pave the way for patient-specific
targeted therapy.REFERENCES
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